Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1979 1
1980 9
1981 33
1982 20
1983 15
1984 4
1985 4
1986 2
1987 5
1988 5
1989 6
1990 3
1991 5
1992 3
1993 5
1994 5
1995 2
1996 4
1997 6
1998 3
1999 4
2000 8
2001 5
2002 6
2003 2
2004 8
2005 2
2007 3
2008 1
2009 6
2010 12
2011 11
2012 6
2013 11
2014 8
2015 17
2016 3
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

245 results

Results by year

Filters applied: . Clear all
Page 1
An update on the current pharmacotherapy for endometrial cancer.
de Haydu C, Black JD, Schwab CL, English DP, Santin AD. de Haydu C, et al. Expert Opin Pharmacother. 2016;17(4):489-99. doi: 10.1517/14656566.2016.1127351. Epub 2015 Dec 23. Expert Opin Pharmacother. 2016. PMID: 26629895 Review.
Solitomab, an EpCAM/CD3 bispecific antibody construct (BiTE®), is highly active against primary uterine and ovarian carcinosarcoma cell lines in vitro.
Ferrari F, Bellone S, Black J, Schwab CL, Lopez S, Cocco E, Bonazzoli E, Predolini F, Menderes G, Litkouhi B, Ratner E, Silasi DA, Azodi M, Schwartz PE, Santin AD. Ferrari F, et al. J Exp Clin Cancer Res. 2015 Oct 17;34:123. doi: 10.1186/s13046-015-0241-7. J Exp Clin Cancer Res. 2015. PMID: 26474755 Free PMC article.
Dual HER2/PIK3CA Targeting Overcomes Single-Agent Acquired Resistance in HER2-Amplified Uterine Serous Carcinoma Cell Lines In Vitro and In Vivo.
Lopez S, Cocco E, Black J, Bellone S, Bonazzoli E, Predolini F, Ferrari F, Schwab CL, English DP, Ratner E, Silasi DA, Azodi M, Schwartz PE, Terranova C, Angioli R, Santin AD. Lopez S, et al. Mol Cancer Ther. 2015 Nov;14(11):2519-26. doi: 10.1158/1535-7163.MCT-15-0383. Epub 2015 Sep 2. Mol Cancer Ther. 2015. PMID: 26333383 Free PMC article.
Solitomab, an EpCAM/CD3 bispecific antibody construct (BiTE), is highly active against primary uterine serous papillary carcinoma cell lines in vitro.
Bellone S, Black J, English DP, Schwab CL, Lopez S, Cocco E, Bonazzoli E, Predolini F, Ferrari F, Ratner E, Silasi DA, Azodi M, Schwartz PE, Santin AD. Bellone S, et al. Am J Obstet Gynecol. 2016 Jan;214(1):99.e1-8. doi: 10.1016/j.ajog.2015.08.011. Epub 2015 Aug 10. Am J Obstet Gynecol. 2016. PMID: 26272866 Free PMC article.
E2F8 as a Novel Therapeutic Target for Lung Cancer.
Park SA, Platt J, Lee JW, López-Giráldez F, Herbst RS, Koo JS. Park SA, et al. J Natl Cancer Inst. 2015 Jun 18;107(9):djv151. doi: 10.1093/jnci/djv151. Print 2015 Sep. J Natl Cancer Inst. 2015. PMID: 26089541 Free PMC article.
Clostridium perfringens enterotoxin C-terminal domain labeled to fluorescent dyes for in vivo visualization of micrometastatic chemotherapy-resistant ovarian cancer.
Cocco E, Shapiro EM, Gasparrini S, Lopez S, Schwab CL, Bellone S, Bortolomai I, Sumi NJ, Bonazzoli E, Nicoletti R, Deng Y, Saltzman WM, Zeiss CJ, Centritto F, Black JD, Silasi DA, Ratner E, Azodi M, Rutherford TJ, Schwartz PE, Pecorelli S, Santin AD. Cocco E, et al. Int J Cancer. 2015 Dec 1;137(11):2618-29. doi: 10.1002/ijc.29632. Epub 2015 Aug 18. Int J Cancer. 2015. PMID: 26060989 Free PMC article.
245 results